|
Reference | Study design | Drugs | Follow-up | Number of patients | Primary endpoint | Results |
|
sDMARDs versus sDMARDs | | | | | | |
Weinblatt et al., 1990 [106] | Randomized double-blind controlled | AUR versus MTX | 36 wks | 138 versus 142 | TJC, SJC, PhGA, PtGA | MTX is more effective and better tolerated than AUR |
Williams et al., 1992 [107] | Randomized double-blind controlled | AUR versus MTX versus AUR + MTX | 48 wks | 115 versus 114 versus 106 | TJC, SJC, PhGA, PtGA | No differences |
Jeurissen et al., 1991 [108, 109] | Randomized double-blind controlled | AZA versus MTX | 48 wks | 33 versus 31 | Ritchie index, TJC, SJC, VAS pain, PtGA | MTX is more efficacious and more rapid than AZA |
Willkens et al., 1995 [110] | Randomized double-blind controlled | AZA versus MTX versus AZA + MTX | 48 wks | 73 versus 67 versus 69 | TJC, SJC, PhGA, PtGA, HAQ, mTSS | MTX is more efficacious than AZA. Trend toward decrease radiographic progression only in MTX |
Drosos et al., 1998 [111] | Randomized open labeled trial | CSA versus MTX | 104 wks | 52 versus 51 | TJC, SJC, VAS pain, Larsen score | No differences in efficacy and radiographic progression |
Ferraccioli et al., 2002 [112] | Open randomized controlled | SSZ versus MTX versus CsA | 24 wks | 42 versus 42 versus 42 | ACR50 | MTX is more efficacious than CSA and SSZ |
Hamilton et al., 2001 [113] | Randomized open labeled trial | GST versus MTX | 48 wks | 72 versus 69 | Paulus response criteria | GST and low dose MTX showed equivalent efficacy, but toxicity was more common in GST |
Rau et al., 2002 [114] | Randomized double-blind controlled | GST versus MTX | 156 wks | 87 versus 87 | Ratingen score | No differences in clinical efficacy and radiographic progression |
Strand et al., 1999 [116] | Randomized double-blind controlled | LFN versus Placebo versus MTX | 52 wks | 182 versus 118 versus 182 | ACR20 | No differences in the efficacy of MTX versu LFN |
Emery et al., 2000 [119] | Randomized double-blind controlled | LFN versus MTX | 52 wks | 501 versus 498 | TJC, SJC, PhGA, PtGA | MTX is more efficacious than LEF, with low 2-yrs radiographic progression |
Bao et al., 2003 [120] | Open randomized controlled | LFN versus MTX | 24 wks | 291 versus 213 | ACR20 | LFN is as effective but safer than MTX |
Haagsma et al., 1997 [121] | Randomized double-blind controlled | SSZ versus MTX versus SSZ + MTX | 52 wks | 34 versus 35 versus 36 | DAS | No differences in efficacy and radiographic progression between MTX and SSZ |
Dougados et al., 1999 [122] | Randomized double-blind controlled | SSZ versus MTX versus SSZ + MTX | 52 wks | 68 versus 69 versus 68 | DAS | No differences in efficacy and radiographic progression between MTX and SSZ |
Capell et al., 2007 [123] | Randomized double-blind controlled | SSZ versus MTX versus SSZ + MTX | 52 wks | 55 versus 54 versus 56 | DAS | No differences in efficacy and radiographic progression between MTX and SSZ |
sDMARDs versus bDMARDs | | | | | | |
Bathon et al., 2000 [16] | Randomized double-blind controlled | ETN 25 mg versus ETN 10 mg versus MTX | 52 wks | 207 versus 208 versus 217 | ACR-N AUC (24 wks), mTSS (52 wks) | ETN had a more rapid rate of improvement than MTX |
Jones et al., 2010 [125] | Randomized double-blind controlled | TCZ versus MTX | 24 wks | 288 versus 284 | ACR20 | TCZ monotherapy is more efficacious than MTX |
Klareskog et al., 2004 [29] | Randomized double-blind controlled | ETN + MTX versus ETN Versus MTX | 52 wks | 231 versus 223 versus 228 | ACR-N AUC (24 wks), mTSS (52 wks) | Combination therapy and ETN are more efficacious than MTX (combo > ETN). |
Breedveld et al., 2006 [14] | Randomized double-blind controlled | ADA + MTX versus ADA versus MTX | 104 wks | 268 versus 274 versus 257 | ACR50, mTSS | Combination therapy was superior to both mono-therapies. No differences between ADA and MTX. |
bDMARDs versus bDMARDs | | | | | | |
Gabay et al., 2013 [127] | Randomized double-blind controlled | TCZ versus ADA | 24 wks | 163 versus 162 | DAS28 | TCZ is superior to ADA |
Weinblatt et al., 2012 [128] | Randomized double-blind controlled | ABT versus ADA | 52 wks | 318 versus 328 | ACR20, mTSS | ABT is noninferior to ADA |
|